doi:[removed]j.neurobiolaging[removed]

First Page		Document Content
Date: 2010-09-23 18:09:24 Endocannabinoid system WIN 55 212-2 Microglia Cannabinoid receptor type 1 Tetrahydrocannabinol Cannabinoid receptor Anandamide CB1 Cannabinoid Biology Cannabinoids Chemistry		doi:[removed]j.neurobiolaging[removed] Add to Reading List Source URL: faculty.psy.ohio-state.edu Download Document from Source Website File Size: 1,27 MB Share Document on Facebook

	Contenido I. Presentación ................................................................................................................................................ 2 II. Organización de la guía ............... DocID: 1v6sA - View Document
	Initial Data from a Phase 2 Multiple Ascending Dose Clinical Trial of SEL-212: Monthly Dosing of SEL-212 Mitigates the Formation of Anti-Drug Antibodies and Enables Sustained Control of Serum Uric Acid in Symptomatic Gou DocID: 1uVOT - View Document
	Phase 2 Clinical Data of SEL-212 in Symptomatic Gout Patients: Monthly Dosing of a Pegylated Uricase (Pegsiticase) with SVPRapamycin Enables Sustained Reduction of Serum Uric Acid Levels by Mitigating Formation of Anti-D DocID: 1uNq4 - View Document
	Identify Case Studies Putting Identify Data to Work Ringgold’s Identify Database and Identify Audit Service provide a wealth of authoritative information on key institutions which participate in the scholarly community DocID: 1tKo8 - View Document
	ÚRAD GEODÉZIE, KARTOGRAFIE A KATASTRA SLOVENSKEJ REPUBLIKY Chlumeckého 2, P. O. Box 57, Bratislava 212 Všetkým katastrálnym odborom okresných úradov DocID: 1rPPO - View Document